Viasat vs State Street SPDR S&P Biotech ETF — how do they compare? Viasat trades at $72.12 (market cap $9.29B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Viasat and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 2,084,105). Which is the better fit depends on your goals — on Pluang, investors hold Viasat for 7 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VSAT | XBI | |
|---|---|---|
Market Cap | $9.29B | $10.11B |
Volume | 2,084,105 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $89.81 | $169.55 |
52-Week Low | $30.35 | $104.99 |
Typical Hold Time | 7 Days | 38 Days |
Enterprise Value | $14.48B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →